191 related articles for article (PubMed ID: 7518216)
1. Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro.
Baba M; Shigeta S; Yuasa S; Takashima H; Sekiya K; Ubasawa M; Tanaka H; Miyasaka T; Walker RT; De Clercq E
Antimicrob Agents Chemother; 1994 Apr; 38(4):688-92. PubMed ID: 7518216
[TBL] [Abstract][Full Text] [Related]
2. Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442.
Yuasa S; Sadakata Y; Takashima H; Sekiya K; Inouye N; Ubasawa M; Baba M
Mol Pharmacol; 1993 Oct; 44(4):895-900. PubMed ID: 7694070
[TBL] [Abstract][Full Text] [Related]
3. Three-drug combination of MKC-442, lamivudine and zidovudine in vitro: potential approach towards effective chemotherapy against HIV-1.
Piras G; Nakade K; Yuasa S; Baba M
AIDS; 1997 Mar; 11(4):469-75. PubMed ID: 9084794
[TBL] [Abstract][Full Text] [Related]
4. The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds.
Brennan TM; Taylor DL; Bridges CG; Leyda JP; Tyms AS
Antiviral Res; 1995 Mar; 26(2):173-87. PubMed ID: 7541619
[TBL] [Abstract][Full Text] [Related]
5. Complete inhibition of viral breakthrough by combination of MKC-442 with AZT during a long-term culture of HIV-1 infected cells.
Okamoto M; Makino M; Yamada K; Nakade K; Yuasa S; Baba M
Antiviral Res; 1996 Jun; 31(1-2):69-77. PubMed ID: 8793010
[TBL] [Abstract][Full Text] [Related]
6. Synergistic inhibition of human immunodeficiency virus type 1 replication by 5-ethyl-1-ethoxymethyl-6-(phenylthio)uracil (E-EPU) and azidothymidine in vitro.
Baba M; Ito M; Shigeta S; Tanaka H; Miyasaka T; Ubasawa M; Umezu K; Walker RT; De Clercq E
Antimicrob Agents Chemother; 1991 Jul; 35(7):1430-3. PubMed ID: 1929304
[TBL] [Abstract][Full Text] [Related]
7. Biological and biochemical anti-HIV activity of the benzothiadiazine class of nonnucleoside reverse transcriptase inhibitors.
Buckheit RW; Fliakas-Boltz V; Decker WD; Roberson JL; Pyle CA; White EL; Bowdon BJ; McMahon JB; Boyd MR; Bader JP
Antiviral Res; 1994 Sep; 25(1):43-56. PubMed ID: 7529014
[TBL] [Abstract][Full Text] [Related]
8. BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine.
Richman D; Rosenthal AS; Skoog M; Eckner RJ; Chou TC; Sabo JP; Merluzzi VJ
Antimicrob Agents Chemother; 1991 Feb; 35(2):305-8. PubMed ID: 1708976
[TBL] [Abstract][Full Text] [Related]
9. Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro.
Chong KT; Pagano PJ; Hinshaw RR
Antimicrob Agents Chemother; 1994 Feb; 38(2):288-93. PubMed ID: 7514857
[TBL] [Abstract][Full Text] [Related]
10. Highly potent and selective inhibition of human immunodeficiency virus type 1 by a novel series of 6-substituted acyclouridine derivatives.
Baba M; De Clercq E; Tanaka H; Ubasawa M; Takashima H; Sekiya K; Nitta I; Umezu K; Walker RT; Mori S
Mol Pharmacol; 1991 Jun; 39(6):805-10. PubMed ID: 1711148
[TBL] [Abstract][Full Text] [Related]
11. Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor.
McMahon JB; Buckheit RW; Gulakowski RJ; Currens MJ; Vistica DT; Shoemaker RH; Stinson SF; Russell JD; Bader JP; Narayanan VL; Schultz RJ; Brouwer WG; Felauer EE; Boyd MR
J Pharmacol Exp Ther; 1996 Jan; 276(1):298-305. PubMed ID: 8558446
[TBL] [Abstract][Full Text] [Related]
12. Epigallocatechin gallate inhibits the HIV reverse transcription step.
Li S; Hattori T; Kodama EN
Antivir Chem Chemother; 2011 Jul; 21(6):239-43. PubMed ID: 21730371
[TBL] [Abstract][Full Text] [Related]
13. Synergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two-drug and three-drug combinations of 3'-azido-3'-deoxythymidine, phosphonoformate, and 2',3'-dideoxythymidine.
Kong XB; Zhu QY; Ruprecht RM; Watanabe KA; Zeidler JM; Gold JW; Polsky B; Armstrong D; Chou TC
Antimicrob Agents Chemother; 1991 Oct; 35(10):2003-11. PubMed ID: 1722077
[TBL] [Abstract][Full Text] [Related]
14. In vitro selection of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine.
Dianzani F; Antonelli G; Turriziani O; Dong G; Capobianchi MR; Riva E
Antiviral Res; 1992 May; 18(1):39-52. PubMed ID: 1384427
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and anti-HIV-1 activity of new MKC-442 analogues with an alkynyl-substituted 6-benzyl group.
Aly YL; Pedersen EB; La Colla P; Loddo R
Arch Pharm (Weinheim); 2007 May; 340(5):225-35. PubMed ID: 17464964
[TBL] [Abstract][Full Text] [Related]
16. Allosteric inhibitors against HIV-1 reverse transcriptase: design and synthesis of MKC-442 analogues having an omega-functionalized acyclic structure.
Tanaka H; Walker RT; Hopkins AL; Ren J; Jones EY; Fujimoto K; Hayashi M; Miyasaka T; Baba M; Stammers DK; Stuart DI
Antivir Chem Chemother; 1998 Jul; 9(4):325-32. PubMed ID: 9875411
[TBL] [Abstract][Full Text] [Related]
17. Synergistic inhibition of human immunodeficiency virus isolates (including 3'-azido-3'-deoxythymidine-resistant isolates) by foscarnet in combination with 2',3'-dideoxyinosine or 2',3'-dideoxycytidine.
Palmer S; Harmenberg J; Cox S
Antimicrob Agents Chemother; 1996 May; 40(5):1285-8. PubMed ID: 8723486
[TBL] [Abstract][Full Text] [Related]
18. Resistance of human immunodeficiency virus type 1 to acyclic 6-phenylselenenyl- and 6-phenylthiopyrimidines.
Nguyen MH; Schinazi RF; Shi C; Goudgaon NM; McKenna PM; Mellors JW
Antimicrob Agents Chemother; 1994 Oct; 38(10):2409-14. PubMed ID: 7840579
[TBL] [Abstract][Full Text] [Related]
19. Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative.
Baba M; Tanaka H; De Clercq E; Pauwels R; Balzarini J; Schols D; Nakashima H; Perno CF; Walker RT; Miyasaka T
Biochem Biophys Res Commun; 1989 Dec; 165(3):1375-81. PubMed ID: 2575380
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of human immunodeficiency virus type 1 replication in vitro by the bisheteroarylpiperazine atevirdine (U-87201E) in combination with zidovudine or didanosine.
Campbell TB; Young RK; Eron JJ; D'Aquila RT; Tarpley WG; Kuritzkes DR
J Infect Dis; 1993 Aug; 168(2):318-26. PubMed ID: 7687641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
